公开(公告)号：US20250059185A1

公开(公告)日：2025-02-20

申请号：US18720022

申请日：2022-12-14

Applicant: Hoffmann-La Roche Inc.

Inventor： Joerg BENZ ,  Maude GIROUD ,  Uwe GRETHER ,  Bernd KUHN ,  Fionn Susannah O'HARA ,  Matthias Beat WITTWER

IPC: C07D471/04 ,  A61K9/20 ,  A61K9/48 ,  A61K31/437 ,  A61K31/444 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/675 ,  C07D487/04 ,  C07D519/00 ,  C07F9/6561

Abstract: The invention provides new MAGL inhibitors having the general formula (II)AB(II) wherein the variables are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

公开(公告)号：US20250057860A1

公开(公告)日：2025-02-20

申请号：US18705190

申请日：2022-10-25

Applicant: EMPHASCIENCE, INC.

Inventor： Rebanta BANDYOPADHYAY

IPC: A61K31/675 ,  A61K9/00 ,  A61K47/10 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34

Abstract: A ready-to-dilute formulation containing 0.5-5 wt. % of a nucleoside or nucleotide pro-drug; 2-15 wt. % pyrrolidone-containing compound; and 65-97.5 wt. % of one or more co-solvent(s) is described, particularly wherein the pyrrolidone-containing compound is polyvinylpyrrolidone and the nucleoside or nucleotide pro-drug is remdesivir. An injectable solution containing the ready-to-dilute formulation and an aqueous diluent is also described, along with methods of treating viral diseases using the injectable solution.

公开(公告)号：US20250057819A1

公开(公告)日：2025-02-20

申请号：US18719122

申请日：2022-12-22

Applicant: INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Inventor： Steven LAPLANTE ,  Richard Boulon ,  Clément Mazeaud ,  Alain Lamarre ,  Laurent Chatel-Chaix

IPC: A61K31/435 ,  A61K31/055 ,  A61K31/135 ,  A61K31/138 ,  A61K31/426 ,  A61K31/496 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/5415 ,  A61K31/58 ,  A61K31/593 ,  A61K31/675 ,  A61K31/7068 ,  A61P31/14

Abstract: A combination comprising tilorone/nelfinavir; tilorone/molnupinavir; tilorone/remdesivir; tilorone/alfacalcidol: tilorone/clofazimine; tilorone/danazol; tilorone/manidipine; tilorone/sertraline; tilorone/trifluoperazine; remdesivir/hexachlorophene; remdesivir/mycophenolate; mycophenolate/hexachlorophene; mycophenolate/nelfinavir; or mycophenolate/nitazoxanide. This combination can be used for blocking the replication of a coronavirus in a coronavirus-infected cell, for treating an infection by a coronavirus in a subject, for treating a coronavirus-related disease in a subject, and/or for reducing the risk of developing a coronavirus-related disease or the severity of a coronavirus-related disease in a subject.

公开(公告)号：US20250051376A1

公开(公告)日：2025-02-13

申请号：US18717626

申请日：2022-12-07

Applicant: PHARMGEN SCIENCE, INC.

Inventor： Marie YEO ,  JeDo OH ,  SeulAe LEE ,  SangHak LEE ,  HyeYoun KIM ,  HeeDeok PARK ,  EuiSang HAN ,  DongKyu KIM ,  DoHyung LEE ,  SeungHee KANG

IPC: C07F9/6561 ,  A61K31/675 ,  A61P1/04

Abstract: The invention relates to benzimidazole derivative compounds represented by Formula 1 or Formula 2 showing a gastric acid secretion inhibitory effect, a pharmaceutical composition comprising the compounds as an active ingredient, and the use thereof.

公开(公告)号：US12215390B2

公开(公告)日：2025-02-04

申请号：US18056967

申请日：2022-11-18

Applicant: BIOTHERANOSTICS, INC.

Inventor： Yi Zhang ,  Catherine A. Schnabel

IPC: C12Q1/6886 ,  A61K31/337 ,  A61K31/513 ,  A61K31/675 ,  A61K31/704 ,  A61K45/06

Abstract: Methods of determining risk of recurrence of a breast cancer of a subject are provided. Also provided are methods of predicting responsiveness to a therapy of a breast cancer of a subject. Additionally, methods of recommending treatment for a subject that has breast cancer are provided. Further provided are methods of treating a subject that has breast cancer. Systems for performing described methods are also provided.

公开(公告)号：US12213979B2

公开(公告)日：2025-02-04

申请号：US16955391

申请日：2018-12-21

Applicant: Genzyme Corporation

Inventor： Alexandra Joseph ,  Johnson Tran ,  Susan M. Richards

IPC: A61K31/519 ,  A61K9/00 ,  A61K31/365 ,  A61K31/52 ,  A61K31/675 ,  A61K31/69 ,  A61K38/13 ,  A61K38/47 ,  A61K39/395 ,  A61P3/00 ,  C12Q1/6883 ,  G01N33/68 ,  A61K39/00

Abstract: The present application provides methods of treating a disease, such as Pompe disease, in a subject, comprising detecting an erythropoiesis biomarker in a sample of the subject after administration of methotrexate and a therapeutic agent to the subject, and administering further treatment with or without concurrently administering additional immune tolerance induction or immunosuppression therapy based on the level of the erythropoiesis biomarker. Further provided by the present application are methods and kits for assessing the level of immune tolerance to a therapeutic agent in a subject based on detection of an erythropoiesis biomarker after administration of methotrexate and the therapeutic agent to the subject.

公开(公告)号：US20250032609A1

公开(公告)日：2025-01-30

申请号：US18777075

申请日：2024-07-18

Applicant: Vaccinex, Inc.

Inventor： Elizabeth E. Evans ,  Ernest S. Smith ,  Maurice Zauderer

IPC: A61K39/395 ,  A61K31/675 ,  A61K35/15 ,  A61K38/20 ,  A61K39/00 ,  A61P35/00 ,  A61P37/04 ,  C07K14/47 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C07K16/40 ,  C12N5/0783 ,  G01N33/50

Abstract: Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.

公开(公告)号：US20250025504A1

公开(公告)日：2025-01-23

申请号：US18716497

申请日：2022-12-05

Applicant: ADICET THERAPEUTICS, INC.

Inventor： Blake AFTAB ,  Francesco GALMI ,  Rose Kamyee LAI ,  Ori MALLER

IPC: A61K35/17 ,  A61K31/675 ,  A61K31/7076 ,  A61K39/00 ,  A61P35/00 ,  C07K14/725 ,  C07K16/28

Abstract: Aspects of the disclosure include methods of effectively treating a relapsed/refractory B cell malignancy in a patient in need thereof who has previously been treated with and ultimately failed at least one, two, or at least three previous therapies. In one example. a method comprises administering to the subject one or more doses comprising a therapeutically effective amount of anti-CD20 CAR γδ T cells that express a chimeric antigen receptor (CAR) comprising a binding domain that specifically binds to CD20 on a malignant B cell to the subject. Following administration, the subject methods optionally further include monitoring for one or more biomarkers of cell activation and/or therapeutic efficacy that inform the need for and/or type of follow-on treatment regimen.

公开(公告)号：US20250025483A1

公开(公告)日：2025-01-23

申请号：US18890082

申请日：2024-09-19

Applicant: Enveric Biosciences Canada Inc.

Inventor： Jillian M. Hagel ,  Peter J. Facchini ,  Chang-Chun Ling

IPC: A61K31/675 ,  A61P25/18

Abstract: Disclosed are novel multi-substituent psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a substituent containing compound.

公开(公告)号：US12201620B2

公开(公告)日：2025-01-21

申请号：US17688222

申请日：2022-03-07

Applicant: The Brigham And Women's Hospital, Inc.

Inventor： Josephine Kahn ,  Siddhartha Jaiswal ,  Benjamin Ebert

IPC: A61K31/4436 ,  A61K31/381 ,  A61K31/675 ,  A61K31/704 ,  A61K31/7068 ,  A61K33/243 ,  A61P35/00

Abstract: The present invention features methods for increasing sensitivity and/or reversing resistance to chemotherapy, methods for treating or preventing a cancer in a subject, methods for treating clonal hematopoiesis of indeterminate potential in a subject, and methods of identifying resistance or sensitivity to chemotherapy in a subject. In some embodiments, the methods contain the step of administering an agent that inhibits the expression or activity of a Protein phosphatase 1D (PPM1D) polypeptide or polynucleotide. The present invention also features compositions for increasing sensitivity and/or reversing resistance to chemotherapy.